In a groundbreaking ruling, CMS has granted Viz.ai the first New Technology Add-on Payment (NTAP) for artificial intelligence software. NTAP, part of the CMS Inpatient Prospective Payment System (IPPS), was set up to support the adoption of cutting-edge technologies that have demonstrated substantial clinical improvement and ensure early availability to Medicare patients. In the US, stroke is the number one cause of long term disability, but is a treatable condition if identified early enough. Viz.ai has been recognized by Forbes, Fast Company, and AuntMinnie as one of the leading AI healthcare companies in the US. The company provides software that improves clinical and financial outcomes1,2 by streamlining acute care, leading to shorter time to treatment, improved patient outcomes, reduced length of stay, and increased number of procedures.

Our flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat. In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification platform to identify LVO strokes in CTA imaging. Most recently, Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral image analysis.